PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8595642-7	1995	Gemfibrozil was significantly more effective than lovastatin in raising total HDL and HDL3 levels and in lowering the IDL plus VLDL:HDL ratio.	Gemfibrozil	0-11	HDL3	Homo sapiens	86-90	
7595182-6	1995	RESULTS: Gemfibrozil increased the concentration of HDL cholesterol (+11.1%) because of the rise of HDL3 cholesterol (34.5%, P < 0.01).	Gemfibrozil	9-20	HDL3	Homo sapiens	100-104	
7595182-11	1995	CONCLUSION: The gemfibrozil-induced elevation of HDL3 and apoA-II may reflect the combined action of LPL, HL and CETP on plasma HDL metabolism.	Gemfibrozil	16-27	HDL3	Homo sapiens	49-53	
8595642-5	1995	Gemfibrozil significantly decreased triglyceride, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein (IDL) levels, the total cholesterol:HDL ratio, and the IDL plus VLDL;HDL ratio, and significantly increased levels of HDL, HDL2, and HDL3.	Gemfibrozil	0-11	HDL3	Homo sapiens	257-261	
8222487-5	1993	These differences may have a physiologic background because the main effect of gemfibrozil is in the stable HDL3 subfraction, rather than in the variable HDL2.	Gemfibrozil	79-90	HDL3	Homo sapiens	108-112	
7755644-9	1995	Furthermore, gemfibrozil increased HDL cholesterol (P < 0.05) and normalised the elevated HDL2 and HDL3 TG content.	Gemfibrozil	13-24	HDL3	Homo sapiens	102-106	
8257455-6	1993	Gemfibrozil increased the concentration of HDL cholesterol (P < 0.01), which was due to the rise of HDL3 cholesterol (+16%), while in the placebo group these values remained unchanged.	Gemfibrozil	0-11	HDL3	Homo sapiens	103-107	
8257455-14	1993	The gemfibrozil-induced elevation of HDL3 and dense HDL subpopulations may reflect the concerted action of LPL, HL and CETP on plasma HDL metabolism.	Gemfibrozil	4-15	HDL3	Homo sapiens	37-41	
1397665-2	1992	After oral treatment with 450 mg gemfibrozil twice daily for 28 days, triglyceride concentrations were reduced in serum, chylomicrons, VLDL and low-density lipoprotein, and total cholesterol concentrations were reduced in serum, chylomicrons and VLDL, and increased in HDL2 plus HDL3.	Gemfibrozil	33-44	HDL3	Homo sapiens	279-283	
1613316-3	1992	Gemfibrozil and lovastatin caused primarily similar alterations in HDL components in HDL2 and HDL3 subfractions.	Gemfibrozil	0-11	HDL3	Homo sapiens	94-98	
1613316-6	1992	Gemfibrozil increased the cholesterol concentrations of HDL2 and HDL3 (p less than 0.05 for both), and lovastatin caused significant increases in HDL2 (p less than 0.05) and HDL3 phospholipids (p less than 0.01).	Gemfibrozil	0-11	HDL3	Homo sapiens	65-69	
1397665-4	1992	It is concluded that gemfibrozil is effective in lowering triglycerides and cholesterol, particularly in triglyceride-rich particles, and raising the cholesterol content of HDL2 plus HDL3.	Gemfibrozil	21-32	HDL3	Homo sapiens	183-187	
2073911-6	1990	Ultracentrifuge analysis in a subsample of the cohort revealed that gemfibrozil raised the level of HDL3-cholesterol but had little effect on HDL2-cholesterol.	Gemfibrozil	68-79	HDL3	Homo sapiens	100-104	
2407250-6	1990	Gemfibrozil increased the level of HDL-cholesterol with the main effect on HDL3-subfraction.	Gemfibrozil	0-11	HDL3	Homo sapiens	75-79	
2504855-8	1989	Gemfibrozil, in contrast, increased HDL3 cholesterol level by 9% because of an enrichment of HDL3 particles in both free cholesterol and cholesteryl esters and lowered the flotation rate of HDL3 (p less than 0.05).	Gemfibrozil	0-11	HDL3	Homo sapiens	36-40	
2504855-8	1989	Gemfibrozil, in contrast, increased HDL3 cholesterol level by 9% because of an enrichment of HDL3 particles in both free cholesterol and cholesteryl esters and lowered the flotation rate of HDL3 (p less than 0.05).	Gemfibrozil	0-11	HDL3	Homo sapiens	93-97	
2504855-8	1989	Gemfibrozil, in contrast, increased HDL3 cholesterol level by 9% because of an enrichment of HDL3 particles in both free cholesterol and cholesteryl esters and lowered the flotation rate of HDL3 (p less than 0.05).	Gemfibrozil	0-11	HDL3	Homo sapiens	93-97